Core Insights - IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative gamma-delta T cell therapies for cancer treatment [3] - The company will participate in the Biotech Showcase 2025, with CEO William Ho presenting on January 14, 2025 [1][2] Company Overview - IN8bio specializes in gamma-delta T cell-based immunotherapies, which can differentiate between healthy and diseased tissues [3] - The lead program, INB-100, targets acute myeloid leukemia (AML) using haplo-matched allogeneic gamma-delta T cells post-hematopoietic stem cell transplant [3] - The company is also investigating autologous DeltEx DRI gamma-delta T cells for glioblastoma in combination with standard care [3] Event Participation - IN8bio will be present at the Biotech Showcase from January 13-15, 2025, and will also be available for meetings during the J.P. Morgan Health Care Conference from January 13-16, 2025 [2] - The panel discussion titled "The Battle Against Cancer: The Armamentarium Keeps Expanding" will take place on January 13, 2025 [2]
IN8bio to Present at Biotech Showcase 2025 in San Francisco